数据里的冲刺力 天方药业 前10个月销售额 达11.8亿元 原料药和部分制剂产品 销往20多个国家和地区 11月13日，记者走进天方药业有限公司（以下简称"天方药业"）盐酸林可霉素发酵生产车间，机械臂在精准 作业；在中控室里，电脑屏幕上实时跳动着生产数据，工作人员只需轻点鼠标，就能对整个生产过程进行实 时监控、调整优化……这座国家级绿色工厂正以"智""绿"双驱的生动实践，奏响高质量发展的动人乐章。 "前10个月我们的销售额达11.8亿元！"天方药业运营管理部经理赖珅说。在医药行业洗牌加剧的背景下，这 份"量稳质升"的答卷，彰显了头部企业的抗风险能力与行业引领力。 深耕医药领域56载，天方药业集研发、生产、销售于一体，拥有5家全资子公司、3个生产基地和1个国家级技 术开发中心，资产总额70多亿元，年产原料药5000余吨、口服固体制剂约70亿片、小容量注射剂近8亿 支。"天方"商标成为中国医药界的"金字招牌"。 天方药业螺旋霉素原料药年产能190吨，年产值1.8亿元，占全球80%以上的市场份额；盐酸林可霉素原料药 以30%的全球占比稳居行业前三，成为抗生素原料药领域的价格风向标。公司两款核心产品通过美国FDA、 ...

Core Viewpoint - Zhuohe Pharmaceutical Group Co., Ltd. is a comprehensive enterprise focusing on drug research and development, sales, and marketing authorization holder (MAH), with a strategy that combines raw materials and formulations, innovative drugs, and specialty generics, aiming for both domestic and global markets [1] Group 1: Talent and Innovation - Talent is a strong driving force for innovation in the biopharmaceutical sector, and the company has implemented a comprehensive employee quality improvement system, including business training and skill competitions [2] - The company has established a "1+1" mentor training model to cultivate young talents and has recognized several individuals as high-level innovative talents at various governmental levels [2] - The head of the R&D analysis department has led the team to overcome challenges in multiple new drug projects and has been recognized for her contributions, including a national invention patent [2] Group 2: Innovation System - The company emphasizes that R&D innovation is the source of its development and has established several provincial-level research centers and specialized R&D platforms [3] - Currently, the company has over 70 ongoing research projects in various disease areas and has received 22 domestic and international invention patents, with over 100 patent applications filed [3] - Notable achievements include the approval of a traditional Chinese medicine innovative drug and the advancement of a new generation JAK1 selective inhibitor into phase III clinical trials [3] Group 3: Global Market Expansion - Zhuohe Pharmaceutical is actively expanding its international business, with 13 raw material products certified in major markets, including the U.S., EU, and Japan [4] - The company has achieved significant market presence, with its raw material product, Neomycin sulfate, holding over 50% of the global high-end market [4] - Recent milestones include FDA registration for its oral formulation workshop and the approval of a new drug application for a specific capsule, marking entry into mainstream international markets [4]